Induction-maintenance of Lopinavir/r in HIV-infected Subjects
Study ACA-ARGE-04-001 A Pilot, Open-Label Study Assessing Safety, Tolerability, Efficacy of a Simplified Lopinavir/Ritonavir Induction/Maintenance Therapy in HIV-Infected Subjects on Their First Protease Inhibitor-Based Regimen.
Sponsor: Abbott
Listed as NCT00159224, this PHASE4 trial focuses on HIV Infections and remains completed. Sponsored by Abbott, it has been updated 7 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Apr 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott
- Fundación Huésped
For direct contact, visit the study record on ClinicalTrials.gov .